BACKGROUND: Bilateral thoracoscopic splanchnicectomy is a minimally invasive method of treating pain in patients with chronic pancreatitis. It offers good, short-term pain relief, but long-term success is difficult to predict. We analyze long-term results and identify factors predicting success of splanchnicectomy. METHODS: A total of 75 consecutive chronic pancreatitis patients underwent bilateral thoracoscopic splanchnicectomy with long term follow-up (>or=1 year). Treatment success was analyzed using the Kaplan-Meier method, and possible predictive factors (etiology, gender, onset of pancreatitis, previous pancreatitis-related surgery, opioid use, pathology at imaging, technical success, and post-splanchnicectomy complications) via the Cox proportional hazards regression model. We compared patients with long-term pain relief, patients who failed the procedure within 1 year, and those who had pain recurrence after > 1 year. Further treatments after failed splanchnicectomy were evaluated. RESULTS: A total of 66 patients (88%) were on continuous opioids; 47 (63%) had prior pancreatitis-related interventions. Treatment was successful in 52% of patients at 12 months, 38% at 24 months, and 28% at 48 months. At the end of follow-up, 21 patients (28%) reported pain relief, of whom 13 were completely pain free without any additional treatment. Pancreatic surgery after failed splanchnicectomy relieved pain in only 13% of patients. Technical success was the only independent factor significantly associated with successful splanchnicectomy outcome (P = .03). Preoperative opioid use showed a strong tendency to be associated with unsuccessful outcome (P = .07). CONCLUSION: Splanchnicectomy offers prolonged (>4 years) benefit in 1 of 4 patients with severe chronic pancreatitis pain. Prior opioid use may adversely impact pain relief after splanchnicectomy.
BACKGROUND: Bilateral thoracoscopic splanchnicectomy is a minimally invasive method of treating pain in patients with chronic pancreatitis. It offers good, short-term pain relief, but long-term success is difficult to predict. We analyze long-term results and identify factors predicting success of splanchnicectomy. METHODS: A total of 75 consecutive chronic pancreatitispatients underwent bilateral thoracoscopic splanchnicectomy with long term follow-up (>or=1 year). Treatment success was analyzed using the Kaplan-Meier method, and possible predictive factors (etiology, gender, onset of pancreatitis, previous pancreatitis-related surgery, opioid use, pathology at imaging, technical success, and post-splanchnicectomy complications) via the Cox proportional hazards regression model. We compared patients with long-term pain relief, patients who failed the procedure within 1 year, and those who had pain recurrence after > 1 year. Further treatments after failed splanchnicectomy were evaluated. RESULTS: A total of 66 patients (88%) were on continuous opioids; 47 (63%) had prior pancreatitis-related interventions. Treatment was successful in 52% of patients at 12 months, 38% at 24 months, and 28% at 48 months. At the end of follow-up, 21 patients (28%) reported pain relief, of whom 13 were completely pain free without any additional treatment. Pancreatic surgery after failed splanchnicectomy relieved pain in only 13% of patients. Technical success was the only independent factor significantly associated with successful splanchnicectomy outcome (P = .03). Preoperative opioid use showed a strong tendency to be associated with unsuccessful outcome (P = .07). CONCLUSION: Splanchnicectomy offers prolonged (>4 years) benefit in 1 of 4 patients with severe chronic pancreatitis pain. Prior opioid use may adversely impact pain relief after splanchnicectomy.
Authors: Yama Issa; Usama Ahmed Ali; Stefan A W Bouwense; Hjalmar C van Santvoort; Harry van Goor Journal: Surg Endosc Date: 2013-09-06 Impact factor: 4.584
Authors: Stefan A W Bouwense; Marinus A Kempeneers; Hjalmar C van Santvoort; Marja A Boermeester; Harry van Goor; Marc G Besselink Journal: Visc Med Date: 2019-04-04
Authors: Michelle A Anderson; Venkata Akshintala; Kathryn M Albers; Stephen T Amann; Inna Belfer; Randall Brand; Suresh Chari; Greg Cote; Brian M Davis; Luca Frulloni; Andres Gelrud; Nalini Guda; Abhinav Humar; Rodger A Liddle; Adam Slivka; Rachelle Stopczynski Gupta; Eva Szigethy; Jyothsna Talluri; Wahid Wassef; C Mel Wilcox; John Windsor; Dhiraj Yadav; David C Whitcomb Journal: Pancreatology Date: 2015-11-11 Impact factor: 3.996
Authors: Stefan A W Bouwense; Marjan de Vries; Luuk T W Schreuder; Søren S Olesen; Jens B Frøkjær; Asbjørn M Drewes; Harry van Goor; Oliver H G Wilder-Smith Journal: World J Gastroenterol Date: 2015-01-07 Impact factor: 5.742
Authors: Emily R Perito; John F Pohl; Caitlin Bakker; Matthew A Armfield; Bradley Barth; Addison Cuneo; Maria Mascarenhas; Megha Mehta; Sarah Jane Schwarzenberg Journal: Pancreas Date: 2022-02-01 Impact factor: 3.327
Authors: Stefan A W Bouwense; Søren S Olesen; Asbjørn M Drewes; Jan-Werner Poley; Harry van Goor; Oliver H G Wilder-Smith Journal: PLoS One Date: 2012-08-06 Impact factor: 3.240
Authors: Marijtje L A Jongsma; Simone A E Postma; Pierre Souren; Martijn Arns; Evian Gordon; Kris Vissers; Oliver Wilder-Smith; Clementina M van Rijn; Harry van Goor Journal: PLoS One Date: 2011-08-18 Impact factor: 3.240
Authors: Stefan A W Bouwense; Søren S Olesen; Asbjørn M Drewes; Jens B Frøkjær; Harry van Goor; Oliver H G Wilder-Smith Journal: PLoS One Date: 2013-02-06 Impact factor: 3.240
Authors: Malgorzata B Malec-Milewska; Wieslaw Tarnowski; Adam E Ciesielski; Emilia Michalik; Maciej R Guc; Jacek A Jastrzebski Journal: Surg Endosc Date: 2013-04-10 Impact factor: 4.584